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Long-term Clinical Outcome of Phase IIb Clinical Trial of
Percutaneous Injectionwith Holmium-166/Chitosan
Complex (Milican) for the Treatment of
Small Hepatocellular Carcinoma
Ja Kyung Kim,1Kwang-Hyub Han,1Jong Tae Lee,2 Yong Han Paik,1Sang Hoon Ahn,1
Jong Doo Lee,3 Kwan Sik Lee,1Chae Yoon Chon,1and YoungMyoungMoon1
Abstract Purpose:The purpose of this studywas to evaluate the long-term tumor response after phase IIb
clinical study and the safety of percutaneous holmium-166 (166Ho)/chitosan complex injection
(PHI) therapy for small hepatocellular carcinoma as a local ablative treatment. 166Ho is a radioac-
tive isotope derived fromnatural holmium-165.We developed a166Ho/chitosan complex (Milican,
DongWha Pharmaceutical Co., Seoul, Korea) using chitosan as a vehicle to retain the radioactive
material within the tumor.
Experimental Design: Forty patients with single hepatocellular carcinoma <3 cm in maximal
diameter were enrolled in this study.The patients either had refused surgery or were poor surgical
candidates andwere treatedwith only single session of PHI.
Results: Two months after PHI, complete tumor necrosis was achieved in 31of 40 patients
(77.5%) with hepatocellular carcinoma lesions <3 cm and in11of12 patients (91.7%) with hepa-
tocellular carcinoma <2 cm.Tumors recurred in 28 patients during the long-term follow-up period,
ofwhich24 recurredat another intrahepatic site.The1-year and2-year cumulative local recurrence
rates were 18.5% and 34.9%, respectively. The survival rates at 1, 2, and 3 years were 87.2%,
71.8%, and 65.3%, respectively. Transient bone marrow depression was serious adverse event
requiringhospitalization in two patients.
Conclusions: PHI was found to be a safe and novel local ablative procedure for the treatment
of small hepatocellular carcinoma and could be used as a bridge to transplantation. A phase III
randomized active control trial is clearly warranted among a larger study population.
In spite of the high incidence of hepatocellular carcinoma,
treatment options for patients are limited, and hepatocellular
carcinoma remains a significant cause of cancer-related deaths.
A number of modalities have emerged for the treatment of
hepatocellular carcinoma using local ablative therapy. These
include percutaneous ethanol injection therapy (PEIT; refs.
1, 2), hepatic cryotherapy (3), radiofrequency ablation (RFA;
ref. 4), and laser photocoagulation (5). There are cases of cure
in most of small tumors with these procedures; however,
marginal recurrence might be expected, even if the entire tumor
mass was included in the targeted area. To improve the efficacy
of local ablation, selective internal radiation therapy was
attempted using radioisotopes, such as iodine-131 (131I)-
lipiodol (6) or yttrium-90 (90Y) microspheres (7). In selected
patients with hepatocellular carcinoma, treatment with 90Y
microspheres has given positive results (8). However, because
the distribution of the isotope depended on tumor vasculature,
leakage could occur in cases of arteriovenous shunts or difficult
catheterizations. Therefore, it is important to verify biodistri-
bution within the tumor and to quantify any systemic leakage.
To overcome the limitations that have been encountered in
various ablative therapies, we have developed a novel therapy
using another radioisotope, holmium-166 (166Ho). 166Ho is a
product of the neutron activation of holmium-165 and is
predominantly a high-energy h-emitter (Emax = 1.84 MeV) with
radiotherapeutic properties appropriate for ablation therapy. It
also emits g-ray photons (81 keV, 6.2%) detectable by
scintillation imaging (9). Its relatively short half-life (26.8
hours; ref. 10) and proper mean penetration depth (2.2 mm)
permit effective treatment without isolation, and it poses a very
low risk of radiation hazard (11). Microspheres loaded with
radioactive 166Ho have been investigated in several preclinical
studies and have been shown to be potentially useful agents for
internal radiation therapy for hepatic tumors (12–14).
Our previous study using an animal model for hepatocellular
carcinoma showed that the 166Ho was effective in destroying
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tumor tissue without associated radiation damage to neighbor-
ing organs (15). In the current study, we examined a group
of hepatocellular carcinoma patients who participated in a
phase IIb clinical trial of the percutaneous 166Ho/chitosan
complex (166Ho/CHICO, Milican, Dong Wha Pharmaceutical
Co., Seoul, Korea) injection (PHI). The purpose of this
study was to evaluate the long-term therapeutic efficacy
and safety of phase IIb clinical trial of PHI in patients with
tumors <3 cm.
Patients andMethods
Patient selection. Forty patients (27 men and 13 women) with
hepatocellular carcinoma, ages 38 to 83 years (mean, 57.4 years), were
enrolled in a phase IIb clinical study of Milican treatment at the
Severance Hospital in Seoul, Korea, between July 1999 and September
2000. The diagnoses of hepatocellular carcinoma were based on
histopathologic confirmation or radiological findings typical of
hepatocellular carcinoma combined with elevated serum a-fetoprotein
(>200 ng/mL). Some of the patients were poor surgical candidates
because of poor hepatic reserve function, comorbidity, age, or economic
reason, and others rejected surgery because they did not want invasive
management. All agreed to enter this study voluntarily. The criteria for
exclusion were tumors >3 cm, age younger than 18 years, with evidence
of extrahepatic metastasis, invasion of the portal vein or massive shunt,
uncontrolled liver disease decompensation (total bilirubinz 4.0 mg/dL,
aspartate aminotransferase or alanine aminotransferase z 150 IU/L,
gastrointestinal bleeding, encephalopathy, refractory ascites), bleeding
tendency (platelet count <60  109/L after correction or prothrombin
time <60%), low leukocyte count (<2,000/AL), percutaneous injection
not feasible owing to location of the tumor, compromised immune
state, pregnancy or lactation, history of severe allergic reactions
(especially to crab), renal failure, previous radiation treatment of upper
abdomen, acute infection, treatment for hepatocellular carcinoma
within 4 weeks, or inability to give informed consent.
Informed consent was obtained from all participants in this phase IIb
clinical trial, which had been approved by the Investigation and Ethics
Committee of the hospital and by the Korean Food and Drug
Administration.
Preparations of 166Ho/chitosan complex (Milican). The 166Ho
solution [166Ho(NO3)35H2O] was generated at the Korean Atomic
Energy Research Institute (Taejon, Korea). In this study, we used 166Ho/
CHICO. Chitosan is a h-1,4-linked polymer of 2-deoxy-2-amino-D-
glucose derived from the deacetylation of chitin (11) and was supplied
by the Pharmaceutical Development Laboratory of Dong Wha
Pharmaceutical (Kyunggi-do, Korea). On the day of the injection, the
radiolabeled agent was added to nonradiolabeled agent and shaken
vigorously for 2 to 3 minutes to form an injectable solution of 166Ho/
CHICO. The mixture was allowed to stand at room temperature for
30 minutes. Based on the results of phase I clinical trial, the amount of
166Ho/CHICO required to administer a dose 20 mCi/cm tumor
diameter was calculated on the day of injection, and this volume was
injected percutaneously directly into the tumor under ultrasound
guidance.
Clinical methods. The preparations for the PHI procedure were
done according to the methods used for percutaneous needle
aspiration biopsies. With ultrasonographic guidance to target lesion
(Fig. 1A), a 21-gauge, four-holed needle was introduced into the tumor
(Fig. 1B), and the 166Ho/CHICO was injected. The injection was
verified by sonographic demonstration that the tumor lesion had
become hyperechoic (Fig. 1C). Only a single session for each patient of
PHI was planned in this study. On the day of the injection and the
following day, g scans were done to confirm the retention of the
radioisotope in the tumor (Fig. 1D). The concentration of radioactivity
in the blood was also checked at the time of g scanning.
Before the procedure and at 1, 3, and 6 months after the treatment, a
complete blood cell count, routine chemistry, and urinalysis were
conducted. All patients underwent abdominal sonography at 1 month
and received a dual-phase liver spiral computed tomography scan at
2 months after the treatment (Fig. 1E). The ultrasonography was done
to find out early treatment failure. The 2-month computed tomography
scan was done to determine the initial tumor response. The tumor
response was evaluated under WHO tumor response criteria with the
European Association for the Study of the Liver modifications (16),
estimating the reduction in enhanced viable tumor area by spiral
computed tomography. Thereafter, until the end of the study or death,
the patients were evaluated every 3 months with computed tomography
scans, measurement of serum a-fetoprotein, and routine blood tests to
determine the long-term responses of the treatment and the recurrence
of tumors.
The response to PHI was determined to be complete or partial
necrosis or progression based on the findings of the spiral computed
tomography scans at 2 months posttreatment. Tumor necrosis was
defined as a necrotic portion of tumor that was not enhanced on either
the arterial or portal phase of the spiral computed tomography scan.
Local recurrence was diagnosed when enhancing foci were observed
close to, along the edge of, or within the tumor area.
Size increase measured by ultrasonography after 1 month or
incomplete tumor necrosis confirmed by the spiral computed
tomography scan after 2 months was regarded as a therapeutic failure,
and another therapeutic modality was selected, such as surgery or
transcatheter arterial chemoembolization, for the continuation of
treatment.
The side effects and complications of PHI were monitored during the
procedure and for 6 months thereafter and were described according to
the WHO toxicity criteria. In the case of initial abnormal grade at
baseline, the difference between grading scales was regarded as severity.
Toxicity was recorded at most severe state regardless of time.
Statistical analysis. The patients’ baseline characteristics and follow-
up results are presented as the median and range of the values. The rates
of local recurrence, occurrence of new lesions, death, local tumor-free
survival, and overall survival, as well as the cumulative local recurrence
rates and the cumulative tumor-free time from the procedure, were
calculated using the Kaplan-Meier method using SPSS 11.0 software
(version 11; SPSS, Chicago, IL).
Fig.1. Complete tumor necrosis in a 60-year-old female patient withhepatocellular
carcinoma after treatment by percutaneous injection of 166Ho/CHICO. A, a nodule
showing contrast enhancement similar to liver parenchymawas confirmed as
hepatocellular carcinoma.B, the hyperechoic nodulewith peripheral hypoechoic rim
on sonography.C, the nodule showed increased echogenicity after the injection
of 166Ho/CHICO.D, on Gamma scan taken on the day of injection, well-retained
radioisotope confined to the tumor is noted at anterior view. E, the nodule had
become a hypoattenuated lesion on arterial and delayed phase 2 months after the
procedure, which was suggestive of hemorrhagic necrosis of the tumor.
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Results
The clinical characteristics of the patients are summarized
in Table 1. The median tumor diameter was 2.45 cm (range,
1.3-3.0 cm), and the median follow-up duration was 26
months (range, 2-38 months). The median serum a-fetoprotein
level was 160 ng/mL (range, 1.8-5,635.0 ng/mL) before
treatment and 15.8 ng/mL (range, 0.57-2,479 ng/mL) 2 months
after the procedure. The median injected dose of 166Ho was
50.0 mCi (range, 30-60 mCi; Table 1). The distribution of risk
factors for hepatocellular carcinoma was as follows: 28 patients
(71%) were positive for HBsAg, seven patients (17.5%) had
alcoholic liver disease, four patients (10%) were positive for
anti-HCV, and one patient had no history of liver disease.
Of the 40 patients, 29 (72.5%) were treated as first-line
therapy. The diagnoses of 16 patients were confirmed with
biopsy, and the remaining patients were diagnosed based on
typical radiological findings and elevated serum a-fetoprotein.
The tumor locations were mainly in the right lobe (72.5%).
Generally, the PHI procedure was well tolerated in all
patients. The short-term response, assessed on computed
tomography scans done at 2 months after the PHI procedure,
showed that 31 of 40 patients (77.5%) with hepatocellular
carcinoma lesions <3 cm had complete tumor necrosis. Of
12 patients with hepatocellular carcinoma lesions <2 cm, 11
patients (91.7%) had complete tumor necrosis. A partial
response was achieved in four patients (10%), and stable
disease was achieved in four patients (10%). One patient
was lost to follow-up at the time of the short-term response
evaluation.
To assess the long-term response, 31 patients for whom
complete tumor necrosis was achieved were followed. Of these
patients, 11 maintained a complete response status, one patient
had a local recurrence, three patients had local and other
intrahepatic recurrences, and 16 patients had other intrahepatic
recurrences without local recurrence over 26.5 months of
median follow-up duration (range, 9-36 months).
The 1-year and 2-year cumulative local recurrence rates of
enrolled patients were 18.5% and 34.9%, and the 1-year and
2-year cumulative recurrence rates were 66.1% and 69.2%
respectively (Fig. 2). The 1-year, 2-year, and 3-year survival rates
were 87.2%, 71.8%, and 65.3%, respectively (Fig. 3).
Two patients required hospitalization due to transient bone
marrow depression 1 month after the procedure. Minor side
effects after the procedure were noted (Table 2), however,
improved after simple medication or hospitalization with
conservative management.
Discussion
Internal radiation therapy for hepatocellular carcinoma
makes use of an internal radiation source that, owing to the
characteristics of the delivery system, achieves a degree of
Table1. Clinical characteristics of the patients
Characteristics n = 40 (%)
Sex
Male 27
Female 13
Age (y)
Median 58.5
Range 38-83
Tumor size (cm)
Median 2.45
Range 1.3-3.0
AFP before treatment (ng/mL)
Median 160.0
Range 1.8-5635
AFP 2mos after treatment (ng/mL)
Median 15.8
Range 0.57-2479
Dose of 166Ho (mCi)
Median 50.0
Range 30-60
TNMstage*
I 12 (30.0)
II 28 (70.0)
Tumor location
Lateral segment 9 (22.5)
Medial segment 2 (5.0)
Right lobe 29 (72.5)
Abbreviation: AFP, a-fetoprotein.
*According to the modified Unio Internationale Contra Cancrum criteria.
Fig. 2. A, cumulative local recurrence rate at long-term follow up. B, cumulative
intrahepatic recurrence rate at long-term follow-up.
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selective uptake within liver tumors. This selective uptake
permits a high dose of radiation to be delivered to the tumor
tissue with little or no risk of serious radiation hepatitis, gastro-
duodenitis, or pneumonitis.
We have previously presented the results of treatment with
percutaneous injection of 166Ho microaggregates and com-
pared them with those of treatment using segmental trans-
catheter arterial chemoembolization (17).
In this study, biodegradable chitosan, rather than micro-
spheres remained persistently, was used as the vehicle to deliver
and retain 166Ho at the tumor site. Chitosan, which is obtained
from the exoskeletons of crustaceans, such as crab and shrimp,
possesses the useful property of transforming from a liquid to a
gel state depending on the pH of the surrounding environ-
ment. It is a polymer of 2-deoxy-2-amino-D-glucose and is
readily dissolved in water to yield a clear solution under acidic
conditions but is converted to the gel state under neutral or
basic conditions above pH 6 (18), such as those found in
injected tumor tissues, thus effectively holding the bound
holmium in place (19). By exploiting this unique property,
166Ho/CHICO was developed to prevent systemic distribution
of 166Ho, and upon injection, it destroys tumors and pericap-
sular lesions while salvaging the surrounding normal tissue.
In the present study, after the percutaneous administration of
166Ho/CHICO, the concentration of radioactivity in the blood
was low (data not shown), and the cumulative urinary and
fecal excretions of the agent over the period from 0 to 72 hours
were 0.53% and 0.54%, respectively. Suzuki et al. (9) has
shown the suitability of 166Ho/CHICO for local injection by
showing that at 24 hours after the injection, <1% of the total
injected amount was detectable in tissues other than those at
the injected site. 166Ho/CHICO diffuses from the injected site
only minimally because it is transformed into a gel in the
tissues, and because it has an appropriately limited half-life.
In an evaluation of acute toxicity in mice after the i.v. injection
of 166Ho/CHICO, the major effects of the injection of 1 mCi/kg
were limited to the spleen, and the changes in the hematologic
variables were reversible by day 14 after the injection (20).
Mechanism of tumor control by intratumoral injection of
166Ho was revealed in melanoma model. Using high-dose
continuous irradiation with intratumoral injection, the main
cell death mechanism in the central portion is necrosis.
Peripheral tissue, which received a lower radiation dose,
showed growth arrest, as in conventional radiation therapy.
Therefore, growth arrest and necrosis were thought to be the
main cell death mechanisms with this technique (21).
Several radionuclides are used for selective internal radiation
therapy (i.e., 131I, 90Y, and 166Ho). We believe that 166Ho has
several distinctive features over the other currently used
radionuclides. First, 166Ho can be produced from 165Ho, a
naturally abundant element, by an uncomplicated process. In
addition, because 166Ho emits g-rays that permit image
acquisition, it is also suitable for the confirmation of its accu-
mulation at the targeted site and for quantitative dosimetric
Fig. 3. Overall survival rate at long-term follow-up (Kaplan-Meier method).
Table 2. Frequency and grade of side effects during 2 months after the procedure using the CommonTerminology
Criteria forAdverse Effects version 3.0
Toxicity No. patientswithmaximum toxicity grade (n = 40)
G1or1grade drop, n (%) G2 or 2 grade drop, n (%) G3 or 3 grade drop, n (%) G4 or 4 grade drop, n (%)
Injection site pain 1 (2.5) 22 (55.0)
Back pain 7 (17.5) 1 (2.5)
Fever 6 (15.0) 18 (45.0)
Nausea 7 (17.5) 6 (15.0)
Facial edema 1 (2.5) 1 (2.5)
Headache 4 (10.0) 4 (10.0)
Skin rash 5 (12.5)
Hematuria 1 (2.5)
Leucopenia 11 (27.5) 8 (20.0) 1 (2.5)
Anemia 4 (10.0) 1 (2.5) 1 (2.5)
Thrombocytopenia 11 (27.5) 6 (15.0) 2 (5.0) 2 (5.0)
AST/ALTelevation 3 (7.5) 2 (5.0)
Jaundice 1 (2.5)
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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studies. Third, 166Ho has a shorter half-life of 26.8 hours than
131I and 90Y, making it possible to discharge the patient on the
day after the procedure. Finally, the h emissions of 166Ho have
an adequate penetration range for the ablation of tumors,
including pericapsular lesions, while avoiding damage to
adjacent nontumorous tissue. 166Ho deposits 90% of its energy
within an area 2.1 mm in diameter, whereas the remainder is
deposited within an area 2.1 to 8.7 mm in diameter (mean, 2.2
mm; ref. 19). Thus, the patients do not have to be isolated and
need few special precautions.
Compared with other percutaneous ablative therapies, such
as PEIT and RFA, PHI using 166Ho/CHICO also has several
merits complementing other established local therapies. PHI
can be completed in a single session; it causes less pain and
inflammatory reactions than PEIT, which usually requires
multiple sessions. In addition, because necrosis occurs only
after direct contact between the tumor tissue and ethanol,
marginal treatment failure may occur more commonly in PEIT.
In PHI, the penetration of radiation into the tissue surrounding
the injected area can resolve this limitation. RFA has the
advantage of causing necrosis in a large tissue volume in one
session and destroying a predictable amount of tissue in a
reproducible manner. However, RFA requires complex and
expensive equipment and involves a more invasive injection
procedure than either PEIT or PHI. It has been shown that the
location of treatable tumors is more limited for RFA, especially
for tumors near the gallbladder, with subcapsular location or
adjacent to the hepatic hilum where running large vessels occur
(22, 23). Precise puncture and insertion of the large-diameter
radiofrequency electrode is technically more unfeasible than
that of the fine noncutting needle used for PEI or PHI. Tumor
seeding along the puncture tract has been reported for RFA
(22), whereas no tumor seeding has been found in the
puncture tract until now after PHI done at our institute.
In the same manner of other studies, tumor necrosis was
considered where no enhancement was seen on computed
tomography scan. Although there is no absolute proof of
reliability for prediction of tumor necrosis, spiral computed
tomography is recognized as the standard imaging modality for
evaluating the response of hepatocellular carcinoma until now
(24), and further histologic correlation with imaging is needed.
Initially, 40 patients were enrolled for the intention-to-treat
analysis. Although 31 patients (77.5%) showed complete
tumor necrosis after 2 months, four patients had marginal
tumor recurrences during the long-term follow-up period.
Although no control group was in this one-armed phase II
study, comparing with historical data of other therapy, PEIT
achieves complete responses in 70% of patients with hepato-
cellular carcinoma lesions <3 cm and has been considered the
gold standard treatment (25, 26). A recent study reported
similar initial complete response rate (96%) to data in present
study with hepatocellular carcinoma <2 cm and revealed
significant relation between tumor size and complete response
rate (27). The rate of complete response was higher in RFA-
treated group by the same investigators comparing with PEI
(90% versus 80%; ref. 28). In the present study, PHI was
regarded having comparable response rates only after single
session and could thus be another useful percutaneous
therapeutic modality with the merits mentioned above. Further
prospective comparative phase III clinical trial is in the pipeline.
In this study, no patients experienced treatment-related
irreversible adverse events or mortality. However, decreases in
leukocyte and platelet counts, in addition to allergic reactions
to the chitosan component, were observed in some patients.
Two patients (5%) admitted for cytopenia 1 month after the
procedure and underwent bone marrow studies. Although the
cellularity of marrow was decreased, it revealed normal
maturation and normal cellular components. These two
patients were completely recovered with conservative general
care and administration of granulocyte macrophage colony-
stimulating factor. Allergic symptoms and pain were easily
improved following appropriate treatments. The blood radio-
activity counts (data not shown) were found to have a
correlation with the suppression of the hematopoietic system.
Little amount of leakage through hypervascular tissue could be
related. In recent study that analyzed 1,000 cases of RFA, major
complications resulting in hospitalization or secondary proce-
dure were observed in 4.0% of treatments, including neoplastic
seeding (29). Deliberating on wide percent range of adverse
rates after systemic chemotherapy, bone marrow depression in
current study was acceptable to be safe.
In conclusion, the treatment of hepatocellular carcinoma
with PHI is a relatively simple and effective procedure that can
be done with a single, intratumoral injection given percutane-
ously. PHI also can be a bridge therapy to transplantation, as
well as a novel local treatment modality. It causes very little
discomfort and disruption of daily activities for most patients.
A phase III randomized active control trial is clearly warranted
for further testing of the safety and efficacy of PHI among a
larger study population.
Percutaneous 166Ho Injection Therapy
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